Results 81 to 90 of about 14,887 (173)

Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7403-7415, August 2026.
ABSTRACT Aims Elevated lipoprotein(a) [Lp(a)] is a genetic ASCVD risk factor that often persists despite intensive LDL‐C lowering. We compared the efficacy and safety of emerging Lp(a)‐targeted therapies (siRNAs, antisense oligonucleotides and an oral assembly inhibitor) with PCSK9‐directed therapies.
Jihad Abu Zayed, Nada A. Al‐Awamleh, Mahmoud Hamad, Mohammad Ibrahim Mahmoud Hdaib, Hazem Ayesh   +4 more
wiley   +1 more source

Combination of Ezetimibe and Garlic Reduces Serum Lipids and Intestinal Niemann-Pick C1-like 1 Expression More Effectively in Hypercholesterolemic Mice

Avicenna Journal of Medical Biochemistry, 2015
Background Combination therapy plays an important role in the management of cardiovascular disease (CVD). Objectives The aim of this experiment was to study the influence of garlic combined with ezetimibe ...
Mohammadi, Vafaei, Nabi Moradi, Ahmadi, Pourjafar, Abbasi Oshaghi   +5 more
doaj   +1 more source

The lipid-lowering effect of ezetimibe in pure vegetarians

Journal of Lipid Research, 2006
Results of previous studies have shown that ezetimibe (10 mg/day) reduces LDL cholesterol in patients with mild hypercholesterolemia on a normal-cholesterol diet (dietary intake of 200–500 mg/day) by 16–22%.
Jacob J. Clarenbach, Michael Reber, Dieter Lütjohann, Klaus von Bergmann, Thomas Sudhop   +4 more
doaj   +1 more source

Contemporary Management of Aortic Stenosis: Timing of Intervention and Lifetime Valve Management

European Journal of Clinical Investigation, Volume 56, Issue 8, August 2026.
As transcatheter treatment expands to younger and lower‐risk patients, aortic stenosis management is evolving from a single procedure to lifelong valve care. This review highlights the key challenges across the patient journey, from timely diagnosis and optimal intervention to durable valve performance, long‐term surveillance, and repeat intervention ...
Ottavia Cozzi, Thomas Pilgrim
wiley   +1 more source

Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV‐suppressed individuals: 48 weeks and beyond

HIV Medicine, Volume 27, Issue 8, Page 1241-1252, August 2026.
Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang, Ruby Tsz‐shan Kwong, Phillip Chan, Kwok‐wai Lam, Helen Shuk‐ying Chan, Man‐yee Chu, Wilson Lam, Tak‐chiu Wu, Wai‐shing Leung, Sai‐kwong Yung, Wan‐man Ting, Annabel Kai‐tung Choy, Joe Lok‐fung Tung, Jason Ka‐wah Fong, Daniel Kai‐yeung Yeung, Man‐po Lee   +15 more
wiley   +1 more source

The changing epidemiology of human type 2 diabetes–associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities

Journal of Internal Medicine, Volume 300, Issue 2, Page 131-152, August 2026.
Abstract Type 2 diabetes (T2D) is a major global health concern strongly associated with atherosclerosis and subsequent macrovascular complications. These complications are the leading cause of death among T2D patients. Despite a decline in cardiovascular events over the last decade, individuals with T2D still have an approximately doubled risk ...
Dania Al‐Sharify, Jiangming Sun, Andreas Edsfeldt   +2 more
wiley   +1 more source

Ezetimibe interferes with cholesterol trafficking from the plasma membrane to the endoplasmic reticulum in CaCo-2 cells

Journal of Lipid Research, 2007
Niemann-Pick C1-like 1 protein (NPC1L1) is the putative intestinal sterol transporter and the molecular target of ezetimibe, a potent inhibitor of cholesterol absorption.
F. Jeffrey Field, Kim Watt, Satya N. Mathur   +2 more
doaj   +1 more source

Ezetimibe and the risk of new-onset type 2 diabetes: a systematic review and meta-analysis

Annals of Medicine
Background Statins reduce cardiovascular risk but may increase new-onset type 2 diabetes mellitus (NO-T2DM). Ezetimibe, a cholesterol absorption inhibitor, is often added to statins to improve lipid control, yet its impact on NO-T2DM remains uncertain ...
Areej S. Albawa’neh, Mais N. Alqasrawi, Zeina N. Al-Mahayri, Amal Albawaana, Gamila Ahmed, Rami H. Al-Rifai, Bassam R. Ali   +6 more
doaj   +1 more source

Ezetimibe (Zetia) [PDF]

Medical Journal Armed Forces India, 2004
openaire   +2 more sources

Multiply doses of FDC of rosuvastatin and ezetimibe versus rosuvastatin monotherapy in Chinese patients with hypercholesterolemia (ROSE-CH): multicenter, randomized-controlled trial

Lipids in Health and Disease
Objective Rosuvastatin plus ezetimibe improves the lipid-lowering effect through different mechanisms of action. This study intended to compare the efficacy and safety of the fixed-dose combination (FDC) of rosuvastatin/ezetimibe vs.
Xianyou Ji, Jinlan Xia, Hong Zhang, Changjie Ren, Guang Ma, Shenwen Fu, Jun Zhang, Ying Chen, Xuebin Han, Jianming Zhang, Zhengxu Fang, Bo Yang, Baisong Yang, Wenjun Huang, Gang Yin, Hong Qi, Hao Gong, Dongfang Wang, Liuyi Hao, Xiufeng Zhao, Zhaohui Pei, Peijian Wang, Xiaodong Li, Ling Lin, De Li, Zhi Li, Lin Zhang, Bo Yin, Ying Cheng, Zhiqing You, Jianlong Sheng, Jie Wu, Ling Chen, Zhongcai Fan, Wang Zhao, Shuiping Zhao   +35 more
doaj   +1 more source